| $376M | ||
| $350M | ||
| $215M | ||
| $127M | ||
| $107M | ||
| $100M |
Buys | $ | – | |
Sells | $ | – |
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
Over the last 12 months, insiders at Amicus Therapeutics, Inc. have bought $undefined and sold $undefined worth of Amicus Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Amicus Therapeutics, Inc. have bought $75,516 and sold $5.59M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,500 shares for transaction amount of $15,735 was made by WHITMAN BURKE W (director) on 2021‑11‑01.
| Increased Positions | 211 | +68.06% | 133M | +42.03% |
| Decreased Positions | 135 | -43.55% | 125M | -39.58% |
| New Positions | 100 | New | 89M | New |
| Sold Out Positions | 47 | Sold Out | 43M | Sold Out |
| Total Postitions | 386 | +24.52% | 323M | +2.45% |
| Vanguard Group Inc | $421,451.00 | 9.56% | 29.53M | +126,441 | +0.43% | 2025-09-30 |
| Wellington Management Group Llp | $408,533.00 | 9.27% | 28.63M | -495,133 | -1.7% | 2025-09-30 |
| Blackrock, Inc. | $368,865.00 | 8.37% | 25.85M | -2M | -6.11% | 2025-09-30 |
| William Blair Investment Management, Llc | $224,742.00 | 5.1% | 15.75M | +1M | +7.56% | 2025-09-30 |
| Avoro Capital Advisors Llc | $214,407.00 | 4.86% | 15.03M | -3M | -16.53% | 2025-09-30 |
| Millennium Management Llc | $168,526.00 | 3.82% | 11.81M | +4M | +59.13% | 2025-09-30 |
| State Street Corp | $165,003.00 | 3.74% | 11.56M | -5,158 | -0.04% | 2025-09-30 |
| Vestal Point Capital, Lp | $139,133.00 | 3.16% | 9.75M | -2M | -18.07% | 2025-09-30 |
| Citadel Advisors Llc | $117,729.00 | 2.67% | 8.25M | +2M | +38.09% | 2025-09-30 |
| Point72 Asset Management, L.P. | $102,124.00 | 2.32% | 7.16M | +4M | +118.25% | 2025-09-30 |